About i-SEP

The startup develops intraoperative blood auto-transfusers that recover, treat, concentrate, and re-transfuse a patient's own blood during surgery. This technology mitigates the risks of blood compatibility issues and contamination, facilitating faster recovery of red blood cells and platelets in hemorrhagic procedures.

<problem> During hemorrhagic surgeries, patients often require allogeneic blood transfusions, which carry risks of incompatibility, contamination, and post-operative complications. Traditional autotransfusion systems only recover red blood cells, limiting their effectiveness in cases of massive bleeding where platelets are also needed. Blood shortages and the high costs associated with donor blood further compound these challenges. </problem> <solution> i-SEP offers an intraoperative cell salvage technology (IOCS) that recovers, processes, and concentrates both red blood cells and platelets from a patient's own blood during surgery. The *same™* system minimizes the need for allogeneic transfusions, reducing the risk of incompatibility and contamination while restoring the patient's immune system post-operatively. The system's filtration technology allows for the recovery of platelets, which are crucial for hemostasis and stopping bleeding. By reinfusing a patient's own blood components, i-SEP aims to improve patient outcomes, reduce healthcare costs, and alleviate pressure on blood banks. </solution> <features> - Recovers both red blood cells (86%) and platelets (52%) during hemorrhagic surgeries - Employs a filtration process to treat and concentrate blood components - Offers a pre-assembled kit for quick and intuitive installation in 2-3 minutes - Provides filtration cycles aligned with surgical time (6 min / 500 mL) - Features intuitive software for step-by-step system guidance - Maintains stable hematocrit concentration over treatment cycles - Preserves platelet functionality (84%) - Facilitates the restoration of the patient's immune system in post-operative care </features> <target_audience> The primary target audience includes cardiac surgeons, anesthesiologists, perfusionists, and hospital networks seeking to reduce reliance on allogeneic blood transfusions, improve patient blood management, and achieve cost savings. </target_audience> <revenue_model> The company generates revenue through the sale of its *same™* medical device and associated consumables used during surgical procedures. The adoption of i-SEP's technology leads to significant cost savings for healthcare systems by reducing the use of allogeneic blood products. </revenue_model>

What does i-SEP do?

Where is i-SEP located?

i-SEP is based in Nantes, France.

When was i-SEP founded?

i-SEP was founded in 2015.

How much funding has i-SEP raised?

i-SEP has raised 16430000.

Location

Nantes, France

Founded

2015

Funding

16430000

Employees

42 employees

Major Investors

GO CAPITAL

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

i-SEP

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

i-sep.com 2K+

Crunchbase

Founded 2015 – Nantes, France

Funding

Estimated Funding

$10M+

Major Investors

GO CAPITAL

Team (40+)

No team information available.

Company Description

Problem

During hemorrhagic surgeries, patients often require allogeneic blood transfusions, which carry risks of incompatibility, contamination, and post-operative complications. Traditional autotransfusion systems only recover red blood cells, limiting their effectiveness in cases of massive bleeding where platelets are also needed. Blood shortages and the high costs associated with donor blood further compound these challenges.

Solution

i-SEP offers an intraoperative cell salvage technology (IOCS) that recovers, processes, and concentrates both red blood cells and platelets from a patient's own blood during surgery. The *same™* system minimizes the need for allogeneic transfusions, reducing the risk of incompatibility and contamination while restoring the patient's immune system post-operatively. The system's filtration technology allows for the recovery of platelets, which are crucial for hemostasis and stopping bleeding. By reinfusing a patient's own blood components, i-SEP aims to improve patient outcomes, reduce healthcare costs, and alleviate pressure on blood banks.

Features

Recovers both red blood cells (86%) and platelets (52%) during hemorrhagic surgeries

Employs a filtration process to treat and concentrate blood components

Offers a pre-assembled kit for quick and intuitive installation in 2-3 minutes

Provides filtration cycles aligned with surgical time (6 min / 500 mL)

Features intuitive software for step-by-step system guidance

Maintains stable hematocrit concentration over treatment cycles

Preserves platelet functionality (84%)

Facilitates the restoration of the patient's immune system in post-operative care

Target Audience

The primary target audience includes cardiac surgeons, anesthesiologists, perfusionists, and hospital networks seeking to reduce reliance on allogeneic blood transfusions, improve patient blood management, and achieve cost savings.

Revenue Model

The company generates revenue through the sale of its *same™* medical device and associated consumables used during surgical procedures. The adoption of i-SEP's technology leads to significant cost savings for healthcare systems by reducing the use of allogeneic blood products.